Migraine Pipeline Summary

DelveInsight’s, “Migraine - Pipeline Insight, 2026” report provides comprehensive insights about 30+ companies and 32+ pipeline drugs in Migraine pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Migraine: Understanding

Migraine: Overview

Migraine is a neurologic disorder that often causes a strong headache. The headache comes in episodes and sometimes also comes with nausea, vomiting, and sensitivity to light. Migraine is a leading cause of disability worldwide. Approximately 15% of Americans experience migraines. Most people who have migraines feel that people who do not have them often underestimate their condition. The exact cause of migraines is unknown, although they're thought to be the result of temporary changes in the chemicals, nerves and blood vessels in the brain. Migraines affect people’s quality of life and ability to participate in work, family, and social events. Migraines are a leading cause of disability and suffering worldwide.

Migraine symptoms primarily include a severe, throbbing headache, often on one side of the head, which worsens with movement and can disrupt normal activities. Many individuals also experience nausea and vomiting. Sensitivity to light and sound is common, making it difficult to be around bright lights or noise. Some may also feel very hot or cold, accompanied by sweating. Poor concentration and difficulty focusing are often reported as well. These symptoms can vary in intensity and may last for hours or even days, impacting daily functioning.

Migraine pathophysiology involves a complex interaction between neural and vascular mechanisms, mainly through the trigeminovascular system, which transmits pain signals from the meningeal vessels to the brain. Neuronal hyperexcitability, particularly in the cerebral cortex, predisposes individuals to migraines. Activation of trigeminovascular pathways releases neuropeptides like CGRP, causing neurogenic inflammation and pain sensitization. Cortical spreading depression (CSD) may trigger migraine aura, though its role in headache onset is still debated. Migraines are believed to result from dysregulated sensory processing and abnormal brain excitability, influenced by both peripheral and central factors.

Diagnosis of migraine may involve imaging tests if the condition is unusual or severe. Magnetic resonance imaging (MRI) provides detailed images of the brain and blood vessels, helping identify conditions like tumors, strokes, or infections. A computerized tomography (CT) scan uses X-rays to create cross-sectional images, aiding in the detection of brain damage, tumors, or bleeding. These tests help rule out other potential causes of headaches.

There is no cure for migraine headaches, but various treatments can help manage or prevent them. Pain relief is often achieved with over-the-counter (OTC) medications, such as acetaminophen, aspirin, caffeine, or ibuprofen. Preventive medications may be recommended if migraines are severe, frequent, or unresponsive to OTC drugs. These include seizure medications, blood pressure drugs like beta-blockers, antidepressants, and Botox injections. Additionally, CGRP antagonists, such as atogepant, eptinezumab, erenumab, fremanezumab, and galcanezumab, can also help prevent migraines.

"Migraine- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Migraine pipeline landscape is provided which includes the disease overview and Migraine treatment guidelines. The assessment part of the report embraces, in depth Migraine commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Migraine collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Migraine R&D. The therapies under development are focused on novel approaches to treat/improve Migraine.

Migraine Emerging Drugs Chapters

This segment of the Migraine report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Migraine Emerging Drugs

• NT201: Merz Pharma

NT201 is an investigational formulation of botulinum neurotoxin type A being developed by Merz Pharma for multiple neurological and pain-related disorders. It acts by selectively inhibiting the presynaptic release of acetylcholine at the neuromuscular junction through cleavage of SNAP-25, resulting in temporary reduction of excessive muscle activity and abnormal nerve signaling. Owing to its highly purified formulation without complexing proteins, NT201 is designed to provide targeted, localized therapeutic effects with a favorable tolerability profile. The therapy is being investigated across several indications, including essential tremor, lower limb spasticity, migraine, and peripheral neuropathic pain, with multiple late-stage clinical development programs underway. Currently, the drug is being developed in the Phase III stage of its development for the treatment of Migraine.

• Lu AG09222: H. Lundbeck A/S

Lu AG09222 is an investigational monoclonal antibody (mAb) with an innovative mode of action, designed to bind and inhibit pituitary adenylate cyclase-activating polypeptide (PACAP). PACAP has emerged as a neuropeptide implicated in the pathophysiology of migraine and represents a novel target in migraine. Lu AG09222 represents a potential new therapeutic option, targeting a pathway in migraine that is distinct from the CGRP pathway. The HOPE phase II trial demonstrated that Lu AG09222 significantly reduced the number of monthly migraine days compared to placebo (p=0.01) over weeks 1–4 of treatment. Currently, the drug is being developed in the Phase II stage of its development for the treatment of Migraine.

• BHV-2100: Biohaven Therapeutics Ltd.

BHV-2100 is a novel, orally administered small-molecule therapy which acts as a highly selective antagonist of the transient receptor potential melastatin-3 (TRPM3) ion channel, which plays a key role in pain signaling and trigeminal nerve activation. By inhibiting TRPM3, BHV-2100 reduces calcium influx into sensory neurons, suppresses neurogenic inflammation, and decreases the release of pain mediators such as CGRP. Through this differentiated, non-CGRP-targeting mechanism, the drug aims to alleviate migraine pain while minimizing central nervous system adverse effects associated with less selective TRP-channel inhibitors. Currently, the drug is being developed in the Phase II stage of its development for the treatment of Migraine.

• 4ET2124: 4E Therapeutics

4ET2124 is a novel peripherally restricted small-molecule mitogen-activated protein kinase-interacting kinase (MNK) inhibitor which acts by selectively inhibiting MNK1/2, key regulators of protein translation involved in pain signaling and neuroinflammation. By blocking MNK activity, 4ET2124 reduces the production of pro-inflammatory proteins and suppresses peripheral nociceptor sensitization, thereby interrupting migraine-associated pain pathways without affecting the central nervous system. This differentiated, non-opioid mechanism is designed to provide effective migraine relief while minimizing CNS-related adverse effects. Currently, the drug is being developed in the Preclinical stage of its development for the treatment of Migraine.

Further product details are provided in the report……..

Migraine: Therapeutic Assessment

This segment of the report provides insights about the different Migraine drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Migraine

There are approx. 30+ key companies which are developing the therapies Migraine. The companies which have their Migraine drug candidates in the most advanced stage, i.e. Phase III include, Merz Pharma and others.

• Phases

DelveInsight’s report covers around 32+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration

Migraine pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Migraine: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Migraine therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Migraine drugs.

Migraine Report Insights

• Migraine Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Migraine Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Migraine drugs?
• How many Migraine drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Migraine?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Migraine therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Migraine and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Merz Pharma
• H. Lundbeck A/S
• Biohaven Therapeutics Ltd.
• 4E Therapeutics
• Evoimmune ,Inc.
• Ceruvia Lifesciences
• Ipsen Pharma
• Aspeya, Inc.
• Kallyope Inc.
• Mentari Therapeutics
• InMed Pharmaceuticals

Key Products

• NT201
• Lu AG09222
• BHV-2100
• 4ET2124
• EVO756
• BOL-148
• Corabotase
• ASY202
• Elismetrep
• MT-001
• MT-002